• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Pfizer Presents Promising New Immunotherapy Combination Data With INLYTA® In Advanced Renal Cell Carcinoma

    Chelsea Pratt
    Oct. 10, 2016 01:45AM PST
    Biotech Investing

    Pfizer today announced data from an ongoing, investigational Phase 1b study of INLYTA® combined with the checkpoint inhibitor pembrolizumab, a PD-1 inhibitor known as KEYTRUDA®, in treatment-naïve patients with advanced renal cell carcinoma.

    Pfizer Inc. (NYSE:PFE) today announced data from an ongoing, investigational Phase 1b study of INLYTA® (axitinib) combined with the checkpoint inhibitor pembrolizumab (A4061079, NCT02133742), a PD-1 inhibitor known as KEYTRUDA® and marketed by Merck, known as MSD outside the United States and Canada, in treatment-naïve patients with advanced renal cell carcinoma (RCC). The study was designed to establish dosing and evaluate the safety and anti-tumor activity of INLYTA when combined with pembrolizumab in first-line treatment of advanced RCC.
    Preliminary results from a similar, separate study combining INLYTA with
    avelumab (JAVELIN Renal 100, NCT02493751), an investigational, fully
    human anti-PD-L1 IgG1 monoclonal antibody that is being co-developed by
    Merck KGaA, Darmstadt, Germany, and Pfizer were also presented. The data
    suggest evidence of anti-tumor activity for INLYTA in combination with
    avelumab and were presented during a poster discussion session at the
    ESMO 2016 Congress, the annual meeting of the European Society for
    Medical Oncology being held in Copenhagen, Denmark.
    Based on these Phase 1 results, two independent global Phase 3 trials
    evaluating these combinations – INLYTA plus pembrolizumab and INLYTA
    plus avelumab – each compared with SUTENT® (sunitinib) in
    first-line advanced RCC are now enrolling patients.
    “Combining immunotherapy agents with currently approved therapies such
    as INLYTA may provide a meaningful improvement in outcome for patients
    with renal cancer,” said Chris Boshoff, M.D., Ph.D., head of
    immuno-oncology, early development and translational oncology, Pfizer
    Global Product Development. “The results presented today indicate that
    there is a potential additive or synergistic effect between INLYTA and a
    checkpoint inhibitor in RCC.”
    Early indicators from the A4061079 study point to strong response rates
    with the INLYTA/pembrolizumab combination, with 37 patients (71.2%,
    confidence internal 56.9, 82.9) achieving objective responses (three
    complete responses and 34 partial responses); 10 patients had stable
    disease and 5 patients had disease progression.
    Separately, in the JAVELIN Renal 100 study of INLYTA in combination with
    avelumab, five out of six patients treated so far had confirmed partial
    responses (objective response rate 83.3%, 95% confidence interval: 35.9,
    99.6) and one patient with tumor shrinkage not meeting partial response
    criteria had stable disease.
    INLYTA is an oral vascular endothelial growth factor (VEGF) receptor
    inhibitor for the treatment of patients with advanced RCC after failure
    of one prior systemic therapy approved in 63 countries. It was the first
    treatment to demonstrate superior progression-free survival benefit in a
    Phase 3 study versus sorafenib, a tyrosine kinase inhibitor, in
    second-line treatment of advanced RCC.
    About Avelumab
    Avelumab (also known as MSB0010718C) is an investigational fully human
    anti-PD-L1 IgG1 monoclonal antibody. By inhibiting PD-L1 interactions,
    avelumab is thought to enable the activation of T-cells and the adaptive
    immune system. By retaining a native Fc-region, avelumab is thought to
    potentially engage the innate immune system and induce
    antibody-dependent cell-mediated cytotoxicity (ADCC). In November 2014,
    Merck KGaA, Darmstadt, Germany, and Pfizer announced a strategic
    alliance to co-develop and co-commercialize avelumab.
    About INLYTA® (axitinib)
    INLYTA is an oral therapy that is designed to inhibit tyrosine kinases,
    including vascular endothelial growth factor (VEGF) receptors 1, 2 and
    3; these receptors can influence tumor growth, vascular angiogenesis and
    progression of cancer (the spread of tumors). In the U.S., INLYTA is
    approved for the treatment of advanced renal cell carcinoma (RCC) after
    failure of one prior systemic therapy. INLYTA is also approved by the
    European Medicines Agency (EMA) for use in the EU in adult patients with
    advanced RCC after failure of prior treatment with sunitinib or a
    cytokine.
    INLYTA Important Safety Information
    Hypertension including hypertensive crisis has been observed. Blood
    pressure should be well controlled prior to initiating INLYTA. Monitor
    for hypertension and treat as needed. For persistent hypertension,
    despite use of antihypertensive medications, reduce the dose.
    Discontinue INLYTA if hypertension is severe and persistent despite use
    of antihypertensive therapy and dose reduction of INLYTA, and
    discontinuation should be considered if there is evidence of
    hypertensive crisis.
    Arterial and venous thrombotic events have been observed and can be
    fatal. Use with caution in patients who are at increased risk or who
    have a history of these events.
    Hemorrhagic events, including fatal events, have been reported. INLYTA
    has not been studied in patients with evidence of untreated brain
    metastasis or recent active gastrointestinal bleeding and should not be
    used in those patients. If any bleeding requires medical intervention,
    temporarily interrupt the INLYTA dose.
    Cardiac failure has been observed and can be fatal. Monitor for signs or
    symptoms of cardiac failure throughout treatment with INLYTA. Management
    of cardiac failure may require permanent discontinuation of INLYTA.
    Gastrointestinal perforation and fistula, including death, have
    occurred. Use with caution in patients at risk for gastrointestinal
    perforation or fistula. Monitor for symptoms of gastrointestinal
    perforation or fistula periodically throughout treatment.
    Hypothyroidism requiring thyroid hormone replacement has been reported.
    Monitor thyroid function before initiation of, and periodically
    throughout, treatment.
    No formal studies of the effect of INLYTA on wound healing have been
    conducted. Stop INLYTA at least 24 hours prior to scheduled surgery.
    Reversible Posterior Leukoencephalopathy Syndrome (RPLS) has been
    observed. If signs or symptoms occur, permanently discontinue treatment.
    Monitor for proteinuria before initiation of, and periodically
    throughout, treatment. For moderate to severe proteinuria, reduce the
    dose or temporarily interrupt treatment.
    Liver enzyme elevation has been observed during treatment with INLYTA.
    Monitor ALT, AST, and bilirubin before initiation of, and periodically
    throughout, treatment.
    For patients with moderate hepatic impairment, the starting dose should
    be decreased. INLYTA has not been studied in patients with severe
    hepatic impairment.
    Women of childbearing potential should be advised of potential hazard to
    the fetus and to avoid becoming pregnant while receiving INLYTA.
    Avoid strong CYP3A4/5 inhibitors. If unavoidable, reduce the dose.
    Grapefruit or grapefruit juice may also increase INLYTA plasma
    concentrations and should be avoided.
    Avoid strong CYP3A4/5 inducers and, if possible, avoid moderate CYP3A4/5
    inducers.
    The most common (≥20%) adverse events (AEs) occurring in patients
    receiving INLYTA (all grades, vs sorafenib) were diarrhea (55% vs 53%),
    hypertension (40% vs 29%), fatigue (39% vs 32%), decreased appetite (34%
    vs 29%), nausea (32% vs 22%), dysphonia (31% vs 14%), hand-foot syndrome
    (27% vs 51%), weight decreased (25% vs 21%), vomiting (24% vs 17%),
    asthenia (21% vs 14%), and constipation (20% vs 20%).
    The most common (≥10%) grade 3/4 AEs occurring in patients receiving
    INLYTA (vs sorafenib) were hypertension (16% vs 11%), diarrhea (11% vs
    7%), and fatigue (11% vs 5%).
    The most common (≥20%) lab abnormalities occurring in patients receiving
    INLYTA (all grades, vs sorafenib) included increased creatinine (55% vs
    41%), decreased bicarbonate (44% vs 43%), hypocalcemia (39% vs 59%),
    decreased hemoglobin (35% vs 52%), decreased lymphocytes (absolute) (33%
    vs 36%), increased ALP (30% vs 34%), hyperglycemia (28% vs 23%),
    increased lipase (27% vs 46%), increased amylase (25% vs 33%), increased
    ALT (22% vs 22%), and increased AST (20% vs 25%).
    For more information and full Prescribing Information, visit www.pfizer.com.
    About Pfizer Oncology
    Pfizer Oncology is committed to pursuing innovative treatments that have
    a meaningful impact on those living with cancer. As a leader in oncology
    speeding cures and accessible breakthrough medicines to patients, Pfizer
    Oncology is helping to redefine life with cancer. Our strong pipeline of
    biologics, small molecules and immunotherapies, one of the most robust
    in the industry, is studied with precise focus on identifying and
    translating the best scientific breakthroughs into clinical application
    for patients across a wide range of cancers. By working collaboratively
    with academic institutions, individual researchers, cooperative research
    groups, governments and licensing partners, Pfizer Oncology strives to
    cure or control cancer with its breakthrough medicines. Pfizer Oncology
    knows that success in oncology is not measured solely by the medicines
    you manufacture, but rather by the meaningful partnerships you make to
    have a more positive impact on people’s lives. Learn more about how
    Pfizer Oncology is applying innovative approaches to improve the outlook
    for people living with cancer at https://www.pfizer.com/research/therapeutic_areas/oncology.
    Pfizer Inc.: Working together for a healthier worldTM
    At Pfizer, we apply science and our global resources to bring therapies
    to people that extend and significantly improve their lives. We strive
    to set the standard for quality, safety and value in the discovery,
    development and manufacture of healthcare products. Our global portfolio
    includes medicines and vaccines as well as many of the world’s
    best-known consumer healthcare products. Every day, Pfizer colleagues
    work across developed and emerging markets to advance wellness,
    prevention, treatments and cures that challenge the most feared diseases
    of our time. Consistent with our responsibility as one of the world’s
    premier innovative biopharmaceutical companies, we collaborate with
    health care providers, governments and local communities to support and
    expand access to reliable, affordable health care around the world. For
    more than 150 years, Pfizer has worked to make a difference for all who
    rely on us. For more information, please visit us at www.pfizer.com.
    In addition, to learn more, follow us on Twitter at @Pfizer
    and @Pfizer_News,
    LinkedIn,
    YouTube,
    and like us on Facebook at Facebook.com/Pfizer.
    DISCLOSURE NOTICE: The information contained in this release is as of
    October 9, 2016. Pfizer assumes no obligation to update forward-looking
    statements contained in this release as the result of new information or
    future events or developments.

    This release contains forward-looking information about INLYTA
    (axitinib), including a potential indication for INLYTA in combination
    with pembrolizumab (A4061079, NCT02133742) for the treatment of advanced
    renal cell carcinoma (RCC) and a potential indication for INLYTA in
    combination with avelumab (MSB0010718C) for the treatment of advanced
    RCC, including their potential benefits, that involves substantial risks
    and uncertainties that could cause actual results to differ materially
    from those expressed or implied by such statements. Risks and
    uncertainties include, among other things, the uncertainties inherent in
    research and development, including the ability to meet anticipated
    clinical study commencement and completion dates as well as the
    possibility of unfavorable study results, including unfavorable new
    clinical data and additional analyses of existing clinical data; risks
    associated with preliminary data; the risk that clinical trial data are
    subject to differing interpretations, and, even when we view data as
    sufficient to support the safety and/or effectiveness of a product
    candidate, regulatory authorities may not share our views and may
    require additional data or may deny approval altogether; whether and
    when drug applications may be filed in any jurisdictions for any
    potential indications for the combination therapies; whether and when
    any such applications may be approved by regulatory authorities, which
    will depend on the assessment by such regulatory authorities of the
    benefit-risk profile suggested by the totality of the efficacy and
    safety information submitted; decisions by regulatory authorities
    regarding labeling and other matters that could affect the availability
    or commercial potential of the combination therapies; and competitive
    developments.

    A further description of risks and uncertainties can be found in
    Pfizer’s Annual Report on Form 10-K for the fiscal year ended December
    31, 2015, and in its subsequent reports on Form 10-Q, including in the
    sections thereof captioned “Risk Factors” and “Forward-Looking
    Information and Factors That May Affect Future Results,” as well as in
    its subsequent reports on Form 8-K, all of which are filed with the U.S.
    Securities and Exchange Commission and available at 
    www.sec.gov and www.pfizer.com.

    canadaclinical databiopharmaceutical companiesclinical trial dataesmo 2016
    The Conversation (0)

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×